IN8bio's DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer

IN8bio Reports First Quarter 2023 Financial Results and Provides Corporate Update

IN8bio Announces New Preclinical Data in Ovarian Cancer to be Presented at ASGCT 26th Annual Meeting

IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors

IN8bio Announces Oral Presentation of New INB-200 Phase 1 Data in Glioblastoma (GBM) to be Presented at 2023 ASCO Annual Meeting